The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•31 March 2026•

1 min read

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8 Billion Deal

Key Facts

1Eli Lilly (LLY) announced a definitive agreement to acquire Centessa Pharmaceuticals (CNTA).

2Centessa is developing orexin receptor 2 (OX2R) agonists to treat excessive daytime sleepiness and impaired wakefulness disorders.

7 days ago

Create Free Account

Version History

8 additional sources confirmed this story

Version 27 days ago

What changed: The story was updated to include specific financial terms of the deal, including the $7.8 billion total valuation, the $38 per share cash offer, and the positive market reaction for Eli Lilly's stock.

Version 18 days ago

Eli Lilly and Company (LLY) has announced a definitive agreement to acquire Centessa Pharmaceuticals (CNTA) in a deal valued at up to $7.8 billion. Under the terms of the agreement, Lilly will pay $38 per share in cash upfront, valuing the clinical-stage biotechnology firm at approximately $6.3 billion. The acquisition is designed to integrate Centessa’s pipeline of orexin receptor 2 (OX2R) agonists into Lilly’s expanding neuroscience division. Centessa specializes in developing advanced treatments for excessive daytime sleepiness and various wakefulness disorders, marking a significant entry for Lilly into sleep medicine. Shares of Eli Lilly (LLY) rose following the announcement of the specific transaction details. This strategic move underscores Lilly's commitment to addressing unmet medical needs in brain health while diversifying its long-term therapeutic reach.